Patents by Inventor Jennifer Lynne Reed
Jennifer Lynne Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130273071Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
-
Patent number: 8481037Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: GrantFiled: January 14, 2011Date of Patent: July 9, 2013Assignee: MedImmune, LLCInventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
-
Publication number: 20120109097Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: January 14, 2011Publication date: May 3, 2012Applicant: MEDIMMUNE, LLCInventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry D. Watkins
-
Patent number: 7582297Abstract: The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.Type: GrantFiled: April 12, 2004Date of Patent: September 1, 2009Assignee: MedImmune, LLCInventor: Jennifer Lynne Reed
-
Publication number: 20090186038Abstract: The present invention provides prophylactic an therapeutic protocols designed to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managing, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits.Type: ApplicationFiled: February 24, 2009Publication date: July 23, 2009Applicant: Medlmmune, LLCInventor: Jennifer Lynne Reed
-
Publication number: 20090047277Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: June 27, 2007Publication date: February 19, 2009Applicant: MEDIMMUNE, INC.Inventors: Jennifer Lynne REED, Herren Wu, Ying Tang, Julian Davies, Jeffry D. Watkins
-
Publication number: 20080299134Abstract: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.Type: ApplicationFiled: March 17, 2008Publication date: December 4, 2008Applicants: MedImmune, Inc., Ludwig Institute for Cancer ResearchInventors: Jennifer Lynne Reed, William Dall'Acqua, Jacques Van Snick, Jean-Christophe Renauld, Francoise Cormont, Catherine Uyttenhove
-
Patent number: 7371383Abstract: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.Type: GrantFiled: April 11, 2003Date of Patent: May 13, 2008Assignees: MedImmune, Inc., Ludwig Institute for Cancer ResearchInventors: Jennifer Lynne Reed, William Dall'Acqua, Jacques Van Snick, Jean-Christophe Renauld, Francoise Cormont, Catherine Uyttenhove
-
Patent number: 7354584Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: GrantFiled: April 12, 2004Date of Patent: April 8, 2008Assignee: MedImmune, Inc.Inventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry D. Watkins
-
Publication number: 20030219439Abstract: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.Type: ApplicationFiled: April 11, 2003Publication date: November 27, 2003Inventors: Jennifer Lynne Reed, William Dall'Acqua, Jacques Van Snick, Jean-Christophe Renauld, Francoise Cormont